NTLA Q4 2023 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$2M-114.1% YoY

Gross Profit

-$4M228.6% margin

Operating Income

-$140M7297.4% margin

Net Income

-$132M6894.2% margin

EPS (Diluted)

$-1.46

QoQ Revenue Growth

-116.0%

Cash Flow

Operating Cash Flow

-$93M

Free Cash Flow

-$95M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$251M

Stockholders' Equity

$1.1B

Cash & Equivalents

$227M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$2M	$14M	-114.1%
Gross Profit	-$4M	-$86M	+94.9%
Operating Income	-$140M	-$110M	-27.1%
Net Income	-$132M	-$113M	-16.5%